-
Formosa Pharmaceuticals and Eyenovia Inc. Sign Licensing Deal for Ocular Surgery Treatment
•
Taiwan’s Formosa Pharmaceuticals (TPE: 6838) and US-based Eyenovia Inc., (NASDAQ: EYEN) have signed their second licensing and partnership agreement. Under this deal, Eyenovia has acquired exclusive US rights to commercialize APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%), a treatment for inflammation and pain following ocular surgery. The total value of the…
-
Biocytogen Pharmaceuticals Opens US Subsidiary Biocytogen Boston Corp. in Massachusetts
•
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the official start of operations at its US subsidiary, Biocytogen Boston Corp., located in Waltham, Massachusetts. The new 3,400 sq.m. facility boasts advanced amenities and a convenient geographical location, marking a significant expansion as it is three times larger than…
-
CanSino Biologics Receives Halal Certificate for COVID-19 Vaccine in Indonesia
•
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received a halal certificate from Indonesia’s LPPOM MUI for its recombinant novel coronavirus vaccine, which uses an adenovirus type 5 vector. This certification is a significant step for the company as it seeks to expand its vaccine’s reach…
-
Innovent Biologics’ Tafolecimab Receives NMPA Approval for Hypercholesterolemia Treatment
•
China-based Innovent Biologics Inc. (HKG: 1801) has announced that it has received market approval from the National Medical Products Administration (NMPA) for its tafolecimab (IBI306), a recombinant fully human anti-PCSK-9 monoclonal antibody (mAb). The approved indication is for primary hypercholesterolemia, including heterozygous familial and non-familial hypercholesterolemia, as well as mixed…
-
European Commission Approves AbbVie’s Aquipta for Migraine Prevention in Adults
•
The European Commission (EC) has granted marketing approval to AbbVie (NYSE: ABBV) for its drug Aquipta (atogepant), marking a significant milestone in the prevention of migraine in adults with four or more migraine days per month. Aquipta becomes the first once-daily oral calcitonin gene-related peptide (CGRP) receptor antagonist to receive…
-
BMS Announces Positive Phase I/II Results for Repotrectinib in ROS1-Positive NSCLC
•
Bristol-Myers Squibb (BMS, NYSE: BMY) has released new data from a Phase I/II trial featuring the ROS1/TRK blocker repotrectinib, which is being investigated for the treatment of ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). The company celebrated the results, highlighting that the next-generation tyrosine kinase inhibitor (TKI)…
-
Immunofoco’s IMC008 Earns Orphan Drug Designation for Gastric Cancer from FDA
•
Suzhou-based cell therapy developer Immunofoco has announced that it has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its next-generation autologous CAR-T therapy, IMC008, which is being developed to treat gastric cancer. IMC008: A Next-Generation CAR-T Therapy Utilizing SNR TechnologyIMC008 is grounded in Immunofoco’s…
-
Seagen’s Tukysa Meets Primary Endpoint in Phase III Study for HER2+ Breast Cancer
•
Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has announced an update on an ongoing Phase III oncology study involving a combination therapy that includes the HER2 inhibitor Tukysa (tucatinib), one of Seagen’s four marketed drugs that attracted Pfizer’s interest. The trial successfully met…
